Amicus Therapeutics (NASDAQ:FOLD) Sets New 12-Month Low at $9.30

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report)'s share price reached a new 52-week low during trading on Thursday . The company traded as low as $9.30 and last traded at $9.33, with a volume of 393134 shares. The stock had previously closed at $10.14.

Wall Street Analyst Weigh In

FOLD has been the topic of several research reports. JPMorgan Chase & Co. cut their price target on shares of Amicus Therapeutics from $21.00 to $19.00 and set an "overweight" rating on the stock in a report on Monday, March 18th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $22.00 price target on shares of Amicus Therapeutics in a report on Thursday, February 29th.

Amicus Therapeutics Trading Down 6.5 %

The firm has a market cap of $2.81 billion, a PE ratio of -18.59 and a beta of 0.80. The company has a 50-day simple moving average of $11.29 and a 200 day simple moving average of $11.96. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 2.42.

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) last posted its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.05). The firm had revenue of $115.08 million during the quarter, compared to analyst estimates of $115.11 million. Amicus Therapeutics had a negative net margin of 37.96% and a negative return on equity of 119.46%. As a group, sell-side analysts forecast that Amicus Therapeutics, Inc. will post 0.01 earnings per share for the current fiscal year.

Insider Transactions at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $10.07, for a total value of $75,525.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares in the company, valued at approximately $8,928,605.78. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 4,167 shares of the company's stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $14.00, for a total transaction of $58,338.00. Following the completion of the transaction, the chief executive officer now directly owns 871,219 shares in the company, valued at $12,197,066. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $10.07, for a total transaction of $75,525.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares in the company, valued at approximately $8,928,605.78. The disclosure for this sale can be found here. Insiders have sold a total of 55,208 shares of company stock valued at $732,930 in the last ninety days. 2.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Comerica Bank raised its holdings in shares of Amicus Therapeutics by 0.8% during the fourth quarter. Comerica Bank now owns 103,418 shares of the biopharmaceutical company's stock valued at $1,468,000 after acquiring an additional 774 shares during the last quarter. Van ECK Associates Corp increased its position in shares of Amicus Therapeutics by 23.1% during the fourth quarter. Van ECK Associates Corp now owns 4,657 shares of the biopharmaceutical company's stock worth $66,000 after purchasing an additional 873 shares in the last quarter. Arizona State Retirement System raised its stake in Amicus Therapeutics by 2.0% in the 3rd quarter. Arizona State Retirement System now owns 60,770 shares of the biopharmaceutical company's stock valued at $739,000 after purchasing an additional 1,213 shares during the last quarter. Franklin Resources Inc. lifted its holdings in Amicus Therapeutics by 2.3% in the 4th quarter. Franklin Resources Inc. now owns 54,943 shares of the biopharmaceutical company's stock valued at $780,000 after purchasing an additional 1,258 shares in the last quarter. Finally, American International Group Inc. boosted its stake in Amicus Therapeutics by 0.9% during the 4th quarter. American International Group Inc. now owns 141,249 shares of the biopharmaceutical company's stock worth $2,004,000 after purchasing an additional 1,298 shares during the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.